Clinical trials
Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials
Below are recruiting recurrent or metastatic nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 2,384 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06690476RecruitingEarly Phase 1
Study of IPM514 for esophageal cancer
This trial tests a new drug called IPM514 for people with a type of esophageal cancer (squamous cell). It aims to find out if the drug is safe and effective. The trial has different groups for those who have had prior treatment and those who will have surgery after treatment.
BeijingAges 18 years+ - NCT06699602RecruitingPhase 2
Immunotherapy before kidney surgery for high-risk kidney cancer
This trial tests a combination of two immunotherapy drugs (cemiplimab and fianlimab) given before surgery for high-risk kidney cancer that has not spread. The goal is to see if the drugs can help reduce the risk of the cancer coming back or spreading in the future.
Basking Ridge, New JerseyAges 18 years+ - NCT06704152RecruitingPhase 1/Phase 2
A cell therapy for blood cancers after stem cell transplant
This trial tests a new cell therapy (BSB-1001) given after a stem cell transplant to prevent or treat high-risk blood cancers like AML, ALL, or MDS. It is for patients with a specific genetic marker and a matched donor.
Duarte, CaliforniaAges 18–70 - NCT06306014RecruitingPhase 1/Phase 2
Study of a new therapy to prevent C. diff recurrence
This study tests a new live bacteria product (EXL01) given with vancomycin to prevent C. diff from coming back. It is for people who have already had C. diff two or more times and are at high risk of another infection.
AnnecyAges 18 years+ - NCT06314958Recruiting
Follow-up after colorectal cancer treatment
This study follows people who have finished treatment for stage II (high-risk) or stage III colorectal cancer and are now cancer-free. Researchers want to learn more about which factors might predict if the cancer will come back, so they can better personalize follow-up care.
Monrovia, CaliforniaAges 18 years+ - NCT03874052RecruitingPhase 1
Ruxolitinib plus venetoclax and azacitidine for relapsed AML
This early-phase study tests a combination of ruxolitinib with venetoclax, with or without azacitidine, for adults whose acute myeloid leukemia (AML) has come back or does not respond to treatment. It may help by stopping cancer cells from growing and improving blood counts, with the exact plan guided by the study arm you’re assigned to.
Columbus, OhioAges 18 years+ - NCT06708299RecruitingPhase 3
CardiolRx for recurrent pericarditis
This trial tests if CardiolRx can help people with recurrent pericarditis (inflammation of the heart lining) who are stable on an IL-1 blocker and are planning to stop it. Researchers will see if CardiolRx can prevent a recurrence when the current treatment is tapered off.
Phoenix, ArizonaAges 18 years+ - NCT06719232Recruiting
Testing a new way to give bladder treatment without a catheter
This study tests a catheter-free method for delivering medication directly into the bladder. It may help patients with bladder pain, recurrent infections, bladder cancer, or cystitis after radiation or chemotherapy.
BudapestAges 18–80 - NCT06730347RecruitingPhase 2
Study of lorigerlimab for advanced ovarian and other cancers
This trial tests a new drug, lorigerlimab, for people with certain types of ovarian cancer or related cancers that have come back or not responded to treatment. The goal is to see if the drug can help shrink tumors or slow the disease.
Los Angeles, CaliforniaAges 18 years+ - NCT06733766Recruiting
Heat therapy for returning thyroid cancer
This trial tests using ultrasound-guided heat (thermal ablation) to treat thyroid cancer that has come back in the neck after a prior thyroidectomy. The goal is to destroy the recurrent tumor using a needle-like device, avoiding another surgery for patients whose cancer has not spread elsewhere.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06740370Recruiting
TACE with lenvatinib and immunotherapy for ruptured liver cancer
This trial tests a combination of targeted therapy (lenvatinib), immunotherapy (PD-1 inhibitor), and a procedure called TACE (which delivers chemotherapy directly to the liver tumor) for people whose liver cancer has ruptured. The goal is to stop bleeding and shrink the tumor.
Beijing, None SelectedAges 18–75 - NCT06749015Recruiting
Study for BRAFV600E Mutant Metastatic Colorectal Cancer
This trial tests a treatment for people whose colorectal cancer has spread and cannot be removed by surgery, and who have a specific gene change called BRAFV600E. It aims to find out if the treatment can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06767332Recruiting
EMDR for fear of cancer returning in familial melanoma
This study tests whether EMDR therapy can help reduce the fear of cancer coming back in people who have been diagnosed with familial melanoma. If you often worry about your cancer returning, this treatment might help you feel more at ease.
Leiden, South HollandAges 18 years+ - NCT06769828Recruiting
Ga-68-FAPI-46 PET scan for colorectal cancer recurrence with rising CEA
This trial tests a new type of PET scan called Ga-68-FAPI-46 to help find if your colorectal cancer has returned when your CEA levels are rising. It might offer a more accurate way to detect recurrence early.
Taipei, BeitouAges 20–100 - NCT06773312RecruitingPhase 1
Study of BC001 plus Sintilimab and XELOX for advanced stomach cancer
This trial tests a combination of three drugs (BC001, Sintilimab, and XELOX chemotherapy) for people with advanced or metastatic HER-2 negative stomach cancer or cancer where the stomach meets the esophagus. The goal is to see if this combination works better than standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT06774131RecruitingPhase 3
Study of UGN-104 for low-grade upper tract urothelial cancer
This trial tests a new treatment called UGN-104 for people with low-grade upper tract urothelial cancer (a type of cancer in the tube that carries urine from the kidney to the bladder). The treatment is given directly into the kidney area to kill cancer cells without surgery.
Homewood, AlabamaAges 18 years+ - NCT06777979RecruitingPhase 1
CAR T cell therapy for children with hard-to-treat leukemia
This trial tests a special kind of immune cell therapy that targets two markers (CD19 and CD22) on leukemia cells. It is for children and teens whose leukemia has come back multiple times or has not responded to standard treatment.
Memphis, TennesseeAges Up to 21 years - NCT06778031RecruitingPhase 2
Study of SHR-A1811 for HER2-positive bile duct cancer
This trial tests a new drug, SHR-A1811, for people with HER2-positive bile duct cancer that has spread or cannot be removed by surgery. It may help control the cancer if you haven't had other treatments for this stage.
Harbin, HeilongjiangAges 18–75 - NCT06780748RecruitingPhase 2
Light-guided re-surgery for recurrent breast cancer
This trial uses a special light and dye to help surgeons find and remove lymph nodes that might contain cancer cells, in women whose breast cancer has come back in the same area after previous surgery.
Goyang-siAges 18 years+ - NCT06781567RecruitingPhase 2
HG146 for advanced adenoid cystic carcinoma
This trial tests a new drug called HG146 for people with advanced adenoid cystic carcinoma that has progressed despite previous treatments. The goal is to see if HG146 can slow or stop the cancer from growing.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06784921Recruiting
Study of sacituzumab govitecan for HER2-negative breast cancer
This study looks at how well a drug called sacituzumab govitecan works and how safe it is for people with a certain type of breast cancer that has spread (HER2-negative metastatic breast cancer). It aims to understand real-world results for patients in China.
Hangzhou, ZhejiangAges 18–75 - NCT06789848RecruitingPhase 2
Testing two immunotherapy drugs for advanced liver and bile duct cancers
This trial tests two investigational drugs, ligufalimab and cadonilimab, for people with advanced liver cancer (hepatocellular carcinoma, HCC) or bile duct cancer (biliary tract cancer, BTC) that has not responded to previous treatment with an immunotherapy drug. The goal is to see if this combination can shrink tumors or slow cancer growth.
Dallas, TexasAges 18 years+ - NCT06816771RecruitingPhase 2
Pazopanib plus TGI/CIV for recurrent/refractory rhabdomyosarcoma in children
This trial tests a combination of two drugs (pazopanib and TGI/CIV) for children and teens whose rhabdomyosarcoma has come back or hasn't responded to standard treatment. The goal is to see if this combination can shrink tumors or slow the disease.
Jinan, ShandongAges 2–18 - NCT06817694Recruiting
CBT for fear of cancer returning in BRCA1/2 women
This trial tests if cognitive behavioral therapy can reduce fear of cancer recurrence in women with BRCA1/2 mutations who have finished treatment for breast or ovarian cancer. It aims to help you cope with worries about cancer coming back.
Québec, QuebecAges 18 years+
Hear when a new Recurrent or Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 2,384 recruiting recurrent or metastatic nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Recurrent Nasopharyngeal Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Squamous Cell Carcinoma
- Recurrent Nasopharyngeal Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
- Metastatic Renal Cell Carcinoma
- Nasopharyngeal Carcinoma (NPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.